Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $52.4 million.

  • Abeona Therapeutics' Shares Outstanding rose 2072.52% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 2072.52%. This contributed to the annual value of $45.6 million for FY2024, which is 7208.68% up from last year.
  • Per Abeona Therapeutics' latest filing, its Shares Outstanding stood at $52.4 million for Q3 2025, which was up 2072.52% from $51.2 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Shares Outstanding peaked at $52.4 million during Q3 2025, and registered a low of $4.0 million during Q1 2021.
  • In the last 5 years, Abeona Therapeutics' Shares Outstanding had a median value of $21.5 million in 2023 and averaged $24.0 million.
  • Per our database at Business Quant, Abeona Therapeutics' Shares Outstanding tumbled by 9526.25% in 2021 and then soared by 26587.37% in 2023.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Shares Outstanding stood at $5.9 million in 2021, then skyrocketed by 200.94% to $17.7 million in 2022, then soared by 49.69% to $26.5 million in 2023, then surged by 72.09% to $45.6 million in 2024, then rose by 14.8% to $52.4 million in 2025.
  • Its last three reported values are $52.4 million in Q3 2025, $51.2 million for Q2 2025, and $49.0 million during Q1 2025.